Major study backs efficacy of antidepressants
A large-scale review of the most common antidepressants has found them all to be superior to placebo in treating major depression, potentially laying to rest questions over their effectiveness.
Read More
Tag: Lancet
Lancet-published data show potential of GW’s Epidiolex
The Lancet has published data from a Phase III study backing use of GW Pharmaceutical/Greenwich Bioscience’s Epidiolex in patients with Lennox-Gastaut syndrome (LGS).
Read More
PhIII data show benefit of Tecentriq on lung cancer survival
Late-stage trial data published in The Lancet show that Roche’s Tecentriq significantly extended survival in patients with previously-treated advanced non-small cell lung cancer taking the immunotherapy versus those on chemotherapy.
Read More
Statin harms exaggerated, finds major review
A comprehensive review of the efficacy and safety of statins, based on 30 years’ research and published in The Lancet, has concluded that the therapy’s benefits have been underestimated and harms exaggerated.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
